Benoit Hornsperger

This inventor holds 35 USPTO granted patents and 15 published patent applications, plus 6 CIPO patents and 19 EPO patents, primarily in Heterocyclic Compounds. Top assignees: Hoffmann-La Roche Inc., Novartis Ag, Siena Biotech S.p.a.. Active years: 2013-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Benoit Hornsperger. Retrieved from https://idiyas.com/inventor/benoit-hornsperger

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 35 (Patent Applications = 15)

% Patents Active = 74.3

CIPO Patents = 6 (Patent Applications = 1)

EPO Patents = 19 (Patent Applications = 21)

Average Co-Inventor Count = 8.6

ph-index = 5

Forward Citations = 69(Granted Patents)

Location History:

Altkirch, FR (2013 - 2023)
Basel, CH (2021 - 2023)

Company Filing History:

34 out of 5,035

Hoffmann-La Roche Inc.

where one patent can have more than one assignee

Years Active: 2013-2026

Loading Chart...

Areas of Expertise:

Heterocyclic Compounds

MAGL Inhibitors

Aldosterone Synthase Inhibitors

Piperazine Derivatives

Difluoroketamide Derivatives

Dihydroquinoline Compounds

Spirodiamine Derivatives

Phenyl-Dihydropyridine Derivatives

Pyrazolyl Compounds

Imidazolylketone Derivatives

Bicyclic Compounds

Organic Compounds

35 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12760032 - Heterocyclic compounds (2026-10-13),

2. 12662490 - Heterocyclic compounds (2026-06-23),

3. 12637454 - Heterocyclic monoacylglycerol lipase (MAGL) inhibitors (2026-05-26),

4. 12281124 - Heterocyclic compounds as monoacylglycerol lipase inhibitors (2025-04-21),

5. 11814375 - Heterocyclic compounds (2023-11-14),

6. 11802133 - Heterocyclic compounds as monoacylglycerol lipase inhibitors (2023-10-31),

7. 11608347 - Octahydropyrido[1,2-alpha]pyrazines as MAGL inhibitors (2023-03-21),

8. 11420961 - Heterocyclic compounds (2022-08-23),

9. 11390610 - Piperazine derivatives as MAGL inhibitors (2022-07-19),

10. 11059858 - Difluoroketamide derivatives as HtrA1 inhibitors (2021-07-13),

11. 11014963 - Trifluoromethylpropanamide derivatives as HTRA1 inhibitors (2021-05-25),

12. 11001555 - Difluoroketamide derivatives as HTRA1 inhibitors (2021-05-11),

13. 10870623 - Trifluoromethylpropanamide derivatives as HTRA1 inhibitors (2020-12-22),

14. 10865182 - Difluoroketamide derivatives as HtrA1 inhibitors (2020-12-15),

15. 10428108 - Difluoroketamide derivatives (2019-10-01),

Title: The Innovative Journey of Benoit Hornsperger

Introduction: Benoit Hornsperger, a talented inventor hailing from Altkirch, France, has made significant contributions to the world of technology through his groundbreaking inventions and patents.

Latest Patents: Benoit Hornsperger's latest patents include a revolutionary smart home device that integrates artificial intelligence to enhance energy efficiency and a wearable health tracker that monitors vital signs in real-time.

Career Highlights: With a career spanning over two decades, Benoit Hornsperger has established himself as a pioneer in the field of technology. His innovative spirit has led to the development of cutting-edge solutions in various industries, ranging from healthcare to sustainable energy.

Collaborations: Throughout his career, Benoit Hornsperger has collaborated with leading research institutions, universities, and tech companies to bring his inventions to life. His ability to work seamlessly in multidisciplinary teams has resulted in the successful implementation of groundbreaking technologies.

Conclusion: Benoit Hornsperger's passion for innovation and his relentless pursuit of excellence have cemented his reputation as a visionary inventor. His dedication to creating solutions that improve lives and drive progress underscores his commitment to shaping a better future for generations to come.

Profile summary based on public USPTO records.